Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. ProMIS Neurosciences, Inc.
  6. News
  7. Summary
    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ProMIS Neurosciences, Inc. Appoints Dr. David Wishart as Chief Physics Officer

05/27/2021 | 07:30am EDT

ProMIS Neurosciences, Inc. announced the appointment of Dr. David Wishart, Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta, as Chief Physics Officer at ProMIS. Dr. Wishart has been one of the world’s most highly cited scientists for each of the past seven years and brings more than three decades in protein folding and misfolding research to ProMIS, creating depth in this area of therapeutic development for neurodegenerative and other diseases. Dr. Wishart has been studying protein folding and misfolding for more than 30 years using a combination of computational and experimental approaches. These experimental approaches include NMR spectroscopy, circular dichroism, fluorescence spectroscopy, electron microscopy, protein engineering and molecular biology. The computational methods include molecular dynamics, agent-based modeling, bioinformatics and machine learning. Over the course of his career, Dr. Wishart has published more than 430 scientific papers, which have been cited more than 78,000 times, covering many areas of protein science including structural biology, protein metabolism and computational biochemistry. He has been with the University of Alberta since 1995 and is currently a Distinguished University Professor in the Departments of Biological Sciences and Computing Science. He also holds adjunct appointments with the Faculty of Pharmaceutical Sciences and the Department of Pathology and Laboratory Medicine.


ę S&P Capital IQ 2021
All news about PROMIS NEUROSCIENCES, INC.
09/16PROMIS NEUROSCIENCES : to Present at the Second Annual Undruggable Leaders Forum
AQ
09/15PROMIS NEUROSCIENCES : to Present at the Second Annual Undruggable Leaders Forum, Septembe..
AQ
09/15PROMIS NEUROSCIENCES : to Present at the Second Annual Undruggable Leaders Forum September..
PU
09/13PROMIS NEUROSCIENCES : to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conf..
PU
09/01ProMIS Neurosciences Appoints "Accomplished" Biotechnology Executive, Josh Mandel-Brehm..
MT
09/01ProMIS Neurosciences, Inc. Appoints Josh Mandel-Brehm to Its Board of Directors
CI
09/01PROMIS NEUROSCIENCES : appoints accomplished biotechnology executive, Josh Mandel-Brehm, t..
PU
08/25PROMIS NEUROSCIENCES : Completes Public Unit Offering for Gross Proceeds of US$20.1 Millio..
MT
08/25ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering
GL
08/25ProMIS Neurosciences, Inc. announced a financing transaction
CI
More news
Financials
Sales 2020 0,00 M 0,00 M 0,00 M
Net income 2020 -5,66 M -4,47 M -4,47 M
Net cash 2020 1,07 M 0,85 M 0,85 M
P/E ratio 2020 -3,96x
Yield 2020 -
Capitalization 79,9 M 62,9 M 63,1 M
EV / Sales 2019 37 534x
EV / Sales 2020 15 614x
Nbr of Employees -
Free-Float 95,1%
Chart PROMIS NEUROSCIENCES, INC.
Duration : Period :
ProMIS Neurosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Managers and Directors
Elliot Goldstein President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial Officer
Eugene Williams Executive Chairman
Neil R. Cashman Director & Chief Scientific Officer
William W. Wyman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PROMIS NEUROSCIENCES, INC.85.00%63
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634